Compare DexCom, Inc. (DXCM) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Main Street Capital Corporation — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Main Street Capital Corporation trades at $55.61 (market cap $4.97B). The key difference: DexCom, Inc. is far larger — about 5.6× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 8.2% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MAIN | |
|---|---|---|
Market Cap | $28.06B | $4.97B |
Sector | Health | Financials |
52-Week High | $89.53 | $67.54 |
52-Week Low | $54.84 | $49.63 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 8.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
MAIN trades at $55.24, up 4.05% today, with a bullish technical signal from moving averages and ADX indicators. The stock shows strong profitability with an 81.08% net income margin and 14.37% ROE, though recent quarters saw mixed earnings results. Dividend payments remain consistent, supporting income appeal. Revenue declined to $592M in 2025 from $601M in 2024, with a projected further drop to $526M in 2026.
Outlook is cautiously optimistic with a consensus price target of $57.75 offering modest upside. Risks include earnings volatility and potential margin compression. Analyst sentiment leans neutral with 78.57% hold ratings, reflecting balanced near-term expectations amid softening revenue trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
